McKesson (MCK)
(Delayed Data from NYSE)
$550.72 USD
+3.25 (0.59%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $551.01 +0.29 (0.05%) 7:16 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$550.72 USD
+3.25 (0.59%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $551.01 +0.29 (0.05%) 7:16 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
McKesson (MCK) Q2 Earnings Meet Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 30 Earnings Roster: MCK, MASI & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) registers growth at CER across its key operating segments in Q1.
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
New Strong Buy Stocks for October 25th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday:
Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.
McKesson (MCK) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) Pharmaceutical and Specialty Solutions unit is expected to have driven its fiscal Q2 results.
Align Technology (ALGN) Beats on Q3 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology (ALGN) witnessing continued momentum in Invisalign volumes across all geographies
Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View
by Zacks Equity Research
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Quest Diagnostics (DGX) Q3 Earnings Surpass, View Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to accelerate volume growth in Q3.
Cerner's (CERN) AbleVets Buyout to Boost Federal Services
by Zacks Equity Research
Cerner (CERN) expects to close the AbleVets deal in the fourth quarter of 2019.
MCK vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
McKesson (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Intuitive Surgical (ISRG) Beats on Q3 Earnings, View Solid
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from solid segmental contributions in Q3.
Top Ranked Value Stocks to Buy for October 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 18th.
Here's Why You Should Add PRA Health to Your Portfolio Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry.
Here's Why You Should Add Allscripts to Your Portfolio Now
by Zacks Equity Research
Allscripts' (MDRX) focus on innovation makes it a worthy investment pick.
Here's Why You Should Retain Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction continues to raise concern.
Here's Why You Should Hold on to NextGen Healthcare for Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) raises 2019 revenue and earnings per share guidance.
Top Ranked Value Stocks to Buy for October 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 15th.
Here's Why You Should Retain Ecolab (ECL) Stock For Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.